Literature DB >> 1649079

Oxidative glycation and free radical production: a causal mechanism of diabetic complications.

J V Hunt1, S P Wolff.   

Abstract

Glucose may oxidise under physiological conditions and lead to the production of protein reactive ketoaldehydes, hydrogen peroxide and highly reactive oxidants. Glucose is thus able to modify proteins by the attachment of its oxidation derived aldehydes, leading to the development of novel protein fluorophores, as well as fragment protein via free radical mechanisms. The fragmentation of protein by glucose is inhibitable by metal chelators such as diethylenetriamine pentaacetic acid (DETAPAC) and free radical scavengers such as benzoic acid, and sorbitol. The enzymic antioxidant, catalase, also inhibits protein fragmentation. Protein glycation and protein oxidation are inextricably linked. Indeed, using boronate affinity chromatography to separate glycated from non-glycated material, we demonstrate that proteins which are glycated exhibit an enhanced tryptophan oxidation. Our observation that both glycation and oxidation occur simultaneously further supports the hypothesis that tissue damage associated with diabetes and ageing has an oxidative origin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1649079     DOI: 10.3109/10715769109145775

Source DB:  PubMed          Journal:  Free Radic Res Commun        ISSN: 8755-0199


  20 in total

1.  Influence of chronic exercise on red cell antioxidant defense, plasma malondialdehyde and total antioxidant capacity in hypercholesterolemic rabbits.

Authors:  Mohsen Alipour; Mustafa Mohammadi; Nosratollah Zarghami; Nasser Ahmadiasl
Journal:  J Sports Sci Med       Date:  2006-12-15       Impact factor: 2.988

2.  Pyridoxamine protects protein backbone from oxidative fragmentation.

Authors:  Sergei Chetyrkin; Missy Mathis; W Hayes McDonald; Xavier Shackelford; Billy Hudson; Paul Voziyan
Journal:  Biochem Biophys Res Commun       Date:  2011-07-13       Impact factor: 3.575

Review 3.  Prospects for the use of antioxidant therapies.

Authors:  S R Maxwell
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

4.  Advanced Maillard reaction end products are associated with Alzheimer disease pathology.

Authors:  M A Smith; S Taneda; P L Richey; S Miyata; S D Yan; D Stern; L M Sayre; V M Monnier; G Perry
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

5.  Oxidative alterations in the experimental glycation model of diabetes mellitus are due to protein-glucose adduct oxidation. Some fundamental differences in proposed mechanisms of glucose oxidation and oxidant production.

Authors:  J V Hunt; M A Bottoms; M J Mitchinson
Journal:  Biochem J       Date:  1993-04-15       Impact factor: 3.857

6.  Retinal nitro blue tetrazolium staining and catalase activity in rat models of diabetes.

Authors:  H Zhang; C D Agardh; E Agardh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-05       Impact factor: 3.117

7.  Maillard reaction of ribose 5-phosphate generates superoxide and glycation products for bovine heart cytochrome c reduction.

Authors:  Rebecca A Gersten; Lisa M Gretebeck; Gordon Hildick-Smith; Roger K Sandwick
Journal:  Carbohydr Res       Date:  2010-09-18       Impact factor: 2.104

8.  Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease.

Authors:  M A Smith; R K Kutty; P L Richey; S D Yan; D Stern; G J Chader; B Wiggert; R B Petersen; G Perry
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

9.  Protective action on human LDL against oxidation and glycation by four organosulfur compounds derived from garlic.

Authors:  Chu-Chyn Ou; Shyh-Ming Tsao; Ming-Cheng Lin; Mei-Chin Yin
Journal:  Lipids       Date:  2003-03       Impact factor: 1.880

10.  Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus.

Authors:  Gladys Castaño; Lilia Fernández; Rosa Mas; José Illnait; Meylin Mesa; J C Fernández
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.